Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Acquires 22,057 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in Thermo Fisher Scientific by 4.2% during Q2, acquiring an additional 22,057 shares, bringing its total holdings to 545,537 shares.
• Thermo Fisher Scientific reported an EPS of $5.79 for the last quarter, exceeding estimates, with revenues of $11.12 billion, reflecting a 4.9% year-over-year increase.
• Among analysts, there is a general optimism, with a consensus rating of "Moderate Buy" and a target price averaging $584.26 for Thermo Fisher Scientific shares.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 545,537 shares of the medical research company's stock after purchasing an additional 22,057 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's portfolio, making the stock its 18th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned about 0.14% of Thermo Fisher Scientific worth $221,193,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC lifted its position in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. lifted its position in Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its position in Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock valued at $31,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 1.9%

TMO stock opened at $568.42 on Thursday. The company has a market capitalization of $214.64 billion, a PE ratio of 32.88, a P/E/G ratio of 3.22 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm's 50-day moving average is $500.65 and its 200 day moving average is $451.30. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TMO shares. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, October 12th. Finally, Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $584.26.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last 90 days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.